2019
DOI: 10.3390/ijms20215328
|View full text |Cite
|
Sign up to set email alerts
|

PRP and BMAC for Musculoskeletal Conditions via Biomaterial Carriers

Abstract: Platelet-rich plasma (PRP) and bone marrow aspirate concentrate (BMAC) are orthobiologic therapies considered as an alternative to the current therapies for muscle, bone and cartilage. Different formulations of biomaterials have been used as carriers for PRP and BMAC in order to increase regenerative processes. The most common biomaterials utilized in conjunction with PRP and BMAC clinical trials are organic scaffolds and natural or synthetic polymers. This review will cover the combinatorial strategies of bio… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
18
0

Year Published

2021
2021
2023
2023

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 18 publications
(18 citation statements)
references
References 139 publications
(180 reference statements)
0
18
0
Order By: Relevance
“…Given that bone marrow contains a complex environment of many cell populations, the use of BMA clot may represent a viable alternative, able to reduce the costs and drawbacks linked to the expansion of cells from the BM, in terms of regulatory compliance and the investment required for the manipulation and storage of biological materials. To elaborate, obtaining BMAC is invasive, requires closed systems during preparation, and the positive results are strongly correlated with the number of stem cells [ 68 ].…”
Section: Discussionmentioning
confidence: 99%
“…Given that bone marrow contains a complex environment of many cell populations, the use of BMA clot may represent a viable alternative, able to reduce the costs and drawbacks linked to the expansion of cells from the BM, in terms of regulatory compliance and the investment required for the manipulation and storage of biological materials. To elaborate, obtaining BMAC is invasive, requires closed systems during preparation, and the positive results are strongly correlated with the number of stem cells [ 68 ].…”
Section: Discussionmentioning
confidence: 99%
“…7,8,10,11,21 There have been several clinical studies supporting the use of BMAC for the treatment of cartilage lesions. 9,10,[22][23][24][25] As the use of BMAC for osteochondral lesions continues to be evaluated, we offer a technique for use in treating OCD lesions, with tips from our experience in implementing this technique. Another technique has described in which the parent bone of an OCD undergoes microfracture to release mesenchymal cells on the parent bone.…”
Section: Discussionmentioning
confidence: 99%
“…MSCs present in BMAC products are multipotent stem cells and have been used in the orthopedic field due to their strong self-renewal capacity along with the potential to differentiate into all musculoskeletal lineages. MSCs are a secretory organ of cytokines, chemokines, GFs, and anti-inflammatory molecules that promote the recovery of the injured tissue[ 8 ]. According to The International Society for Cellular Therapy Position Statement, there are four minimum criteria for MSC identification: (1) MSCs must be plastic-adherent when cultured under standard conditions; (2) MSCs must demonstrate the capacity for osteogenic, adipogenic, and chondrogenic differentiation; (3) MSCs must express CD73, CD90, and CD105; and (4) MSCs must lack expression of hematopoietic lineage markers ( e.g.…”
Section: Bmacmentioning
confidence: 99%
“…The use of BMAC in clinical trials is relatively new when compared to PRP. However, good to excellent results have been demonstrated, especially in the treatment of chondral lesions[ 8 , 9 ].…”
Section: Introductionmentioning
confidence: 99%